Background {#Sec1}
==========

Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Hepatitis delta virus (HDV) and Human Immunodeficiency Virus Type 1 (HIV-1) are blood borne and can be transmitted from mother to child. Africa bears about two-thirds of the global HIV burden \[[@CR1]\] with women of child-bearing age at higher risk of infection. While the tide of HIV infection is increasing in many countries in sub Saharan africa, Cameroon records a rate of 4.1% in 2015, and HBV infection rate of 4.3 to 11.9% \[[@CR2], [@CR3]\] and 28% of HBeAg \[[@CR2]\] among pregnant women. Children born of HBeAg-positive mothers have a 45.5% chance of infection if no prevention intervention is offered \[[@CR4]\] while only 10.2% may get infected if cesarean section is offered and 28.0% if by vaginal delivery \[[@CR5]\]. We however lack accurate and recent epidemiologic data on HCV infection among pregnant women in Cameroon although low rates have been reported in the early 2000. Meanwhile, HCV RNA-positivity has been associated with the risk of vertical transmission, contributing to a rate of transmission of 4 to 5%. The risk becomes greater if the mother is co-infected with HIV. On the other hand, HDV infects 15 to 20 million people worldwide. In a rural District in northern Cameroon, anti-HDV prevalence of 7.3% among pregnant women was reported \[[@CR6]\] and among adults in Yaounde, 22.7% \[[@CR7]\].

Despite this burden and available information on modes of transmission and prevention of these viruses, prevention and control efforts have not been optimal in low- and middle- income countries (LMIC). To promote the WHO initiative to eliminate viral hepatitis by 2030, the incorporation of other communicable diseases in the ongoing HIV and Syphilis Prevention of Mother-to-child Transmission (PMTCT) Programmes is imperative \[[@CR8]\]. The HIV PMTCT Programme is integrated into the Mother-Newborn and Infant Service in Cameroon, with coverage from 68 to 92%, while the National Early Infant Diagnosis (EID) is at 48%. In spite of the services available for pregnant women at the antenatal clinic (ANC), first antenatal consultation was at 76% in 2016 with 88% of the women who knew their HIV status and of whom 8% were tested at the time of labour.

The AIDS Treatment Guidelines for Cameroon do not incorporate HIV-1 drug resistance (DR) testing at initiation of ART for the pregnant women nor the infants enrolled in the PMTCT Programme. Therefore, the impact of ART in pregnancy and on future therapeutic response of the mother or infant, has not been fully studied. In 2016, 75.7% of pregnant women were on antiretroviral therapy (68.9% of the Centre Region where Yaoundé is situated). In spite of these interventions, a rate of 5.6% of vertical transmission was reported with mother and infant receiving antiretroviral (ARV) drugs \[[@CR9]\].

Resistance to nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) can occur in infants who become infected with HIV in spite the ARV-based interventions. In the KiBS study carried out in Kenya, 67% of infants who were infected despite maternal triple prophylaxis, had drug resistant HIV-1 strains, while in Cameroon a rate of transmitted drug resistance (TDR) of 7% in treatment-naïve pregnant women was reported \[[@CR10]\].

The scope of HBV, HCV, HDV or HIV infection in pregnant women needs to be better understood for resources to be allocated to scale-up the PMTCT Programme and improve the quality of life of infants exposed and/or infected with these viruses. The aims of this study were therefore to determine the seroprevalence of HBV, HCV, HDV and HIV, assess knowledge and attitudes of pregnant women on HBV transmission and prevention, and determine the profile of HIV-1 drug resistance among breastfeeding women who were involved in the PMTCT Programme in Yaoundé, the capital city of Cameroon.

Methods {#Sec2}
=======

Ethical approval to carry out these studies were obtained from the Chantal Biya International Reference Centre for Research on Prevention and Management of HIV/AIDS (CIRCB) Institutional Review Board (IRB).

Selection of study sites and study participants {#Sec3}
-----------------------------------------------

From September 2011 to April 2015, we conducted a cross-sectional study in the antenatal consultation Departments of three tertiary hospitals in Yaoundé, Cameroon. Two groups of women were recruited for these sub studies.

*Virus Seroprevalence, and Knowledge, Attitude and Practice (KAP) Survey among Pregnant Women sub Study (Group 1):* we used a formula to estimate a population proportion with specified absolute precision. The confidence level was 95% and a prevalence of 2.5% of HCV (which is the least compared to the HIV-1, HBsAg or HDV) were used to calculate the sample size of pregnant women. With an absolute precision of 1%, we calculated a sample size of 937 and added 10% for missing data, giving a final sample size of 1030 of women of age above 21 years. We however, recruited 1005 within the study period.

*HIV Drug Resistance among Breastfeeding Women on Antiretroviral Therapy (ART) sub Study (Group 2):* out of 85 HIV-infected women detected in the Group 1 sub study, 50 were enrolled in the PMTCT Programme. They were HBV-negative, HCV-negative, and breastfeeding (for at least 6 weeks) and on ART. Of these, 40 samples were successfully sequenced for prediction of HIV-1 drug resistance or susceptibility.

Data collection and analysis {#Sec4}
----------------------------

Following a written informed consent, a questionnaire (Additional file [1](#MOESM1){ref-type="media"}) was used to collect demographic data, knowledge, attitude, and practices relating to HBV transmission and prevention (Group 1). While in Group 2, data on AIDS treatment history were collected from the participants' hospital records. The data from the questionnaire were analyzed using the EPI Info 7.2 software. The data was summarized using means and standard deviation for quantitative variables and frequencies for qualitative variables. Associations between qualitative variables were done using Fisher's Exact test and the significance level was 5%.

Screening for hepatitis B virus, hepatitis C virus, hepatitis delta virus and HIV infections {#Sec5}
--------------------------------------------------------------------------------------------

HIV-1 antibodies were detected in plasma samples using 2 rapid tests and samples with discordant results were further tested using a fourth generation ELISA (Genscreen ULTRA HIV Ag-Ab). Similarly, the women were screened for HBsAg, HBeAg, anti-HBe, anti-HBc, anti-HCV, anti-HDV by ELISA (Monolisa™). The women diagnosed positive for any of the viruses were interviewed on the awareness of their serological status, and referred to Care services.

Measurement of T lymphocyte CD4 level, plasma HIV-1 RNA load and determination of HIV-1 drug resistance {#Sec6}
-------------------------------------------------------------------------------------------------------

T lymphocyte CD4^+^ cell counts were determined by flow cytometry using the BD FACScalibur™ cytometer \[[@CR11]\] and plasma HIV-1 RNA load using the Abbott RealTi*m*e HIV-1 assay \[[@CR12]\]. To determine specific mutations associated to drug resistance in the protease-reverse transcriptase regions of HIV-1 and genotyping, RNA extraction was done from plasma using QIAamp viral RNA mini kit \[[@CR13]\], amplified over a 1197 base pair (bp) fragment and sequenced directly as previously described \[[@CR14]\] using the Applied BioSystems Model 3130XL Genetic Analyzer \[[@CR15]\].

All nucleotide sequences were automatically aligned with reference sequences of all known HIV-1 Group M subtypes and predominant circulating recombinant forms (CRFs) from the Los Alamos HIV sequence database using CLUSTAL X with minor manual adjustments \[[@CR16]\]. Phylogenetic analyses were conducted using the MEGA software package, and trees were constructed by the neighbor-joining method. The protease-reverse transcriptase DNA sequences were analyzed for mutations associated to drug-resistance using the Stanford University HIV Database genotypic resistance interpretation algorithm \[[@CR17]\].

Results {#Sec7}
=======

I)**General Characteristics of Study Population**

Overall, 1005 pregnant women (Group 1) were included in this study, of age range from 18 to 43 years (mean age of 27.49 ± 5.18 years). A majority of the women were in the third trimester (69.9%) and the gestational age ranged from 6 to 42 weeks with a mean of 29.49 ± 7.39 weeks. Multigravid women were the most represented (68.3%), and gravidity ranged from 1 to 8 pregnancies (Table [1](#Tab1){ref-type="table"}).Table 1Demographic data of Pregnant Women (Group 1; *N* = 1005)CharacteristicsValueMean age27.49 ± 5.18 yearsMean gestational age (at 3rd trimester)29.49 ± 7.39 weeksMean gravidity2.56 ± 1.47 pregnanciesMultigravid68.3%Marital statusFrequency (%) Married62.1 Cohabitation20.2 Single17.8Educational LevelFrequency (%) Secondary school level57.3 Higher level31.6ProfessionFrequency (%) Jobless35.8 Self-employed18.1 Student23.3

Over 50% of the HIV-infected women were diagnosed for HIV infection during pregnancy at their visit to the antenatal clinic. Of these, 36% were tested during the last pregnancy and 19% during prior pregnancies while 45% were tested during Voluntary Testing and Counselling Campaigns.

Group 2 consisted of 50 HIV-infected and breastfeeding women on ART of mean age of 30 (± 4 years), with 50% married. Of these 50, only 40 specimens were analyzed for HIV-1 genotypic drug resistance. All the women were on zidovudine plus lamivudine plus nevirapine (AZT + 3TC + NVP) (Table [2](#Tab2){ref-type="table"}).II)**Knowledge, Attitudes and Practices relating to Hepatitis B Virus Infection**Table 2Demographic data of HIV-infected and Breastfeeding Women on ART (Group 2; *N* = 40)CharacteristicsValueMean age30 ± 4 yearsMarital statusFrequency (%) Married50Educational levelFrequency (%) Secondary school level58Gravidity Modal gravidity2 Modal parity2HAART onsetFrequency (%) Before last pregnancy62.5 During last pregnancy17.5 During current pregnancy20HAART regimen AZT + 3TC + NVP100*AZT*: zidovudine*3TC*: lamivudineNVP: nevirapine

Among women infected with HBV, 5.9% were aware of their status before pregnancy whereas 63.8% of those infected with HIV had known their status before pregnancy (Table [3](#Tab3){ref-type="table"}). Whereas, among the women co-infected, 75% of them had known only about their HIV serological status and not the other virus. Most of the infected women were single with a high mean gravidity compared to those not infected with any of the viruses (*p* \< 0.05).Table 3KAP Survey on HBV Transmission and Prevention MethodsFrequency (%)Awareness of mode of HBV transmission Mother-to-child47.1 Blood transfusion51.5 Sharing of personal objects39.5 Sexual intercourse47.8 Direct contact with body fluid of an infected individual30.8Awareness of HBV prevention methods Usage of personal objects37.4 Fidelity23.7 Abstinence22.5 Vaccination83.3 Condom use30.4Awareness of virus serologic status before study HIV63.8 HBV5.9 HCV0HBV vaccination2.5

The most common method of transmission of HBV reported by the women was blood transfusion (51.5%), while 47.1 and 47.8% knew that HBV could also be transmitted from mother-to-child and through sexual intercourse, respectively. More so, 23.7 and 22.5% reported that HBV can be prevented if fidelity is practiced within married couples, and the use of condoms, respectively. Although 83.3% of the women admitted that vaccination was a means of preventing HBV infection, it was found that only 2.5% had received the hepatitis B vaccine (Table [3](#Tab3){ref-type="table"}).III)**Seroprevalence of HIV-1, HBV, HCV and HDV in Pregnant Women**

Overall, 15.0% (151/1005) of the women were mono-infected for either HIV-1, HBV or HCV. Rate of HCV infection was 0.8%, of HBV (HBsAg+) was 6.4, and 8.5% for HIV-1 (Table [4](#Tab4){ref-type="table"}). No cases of HBV and HCV co-infection were identified while 0.1% (1/1005) was co-infected with HIV-1 and HCV. The age group of 31 to 35 years was most frequently infected with at least one of the viruses (22.8%).Table 4Seroprevalence of HIV-1, HBV, HCV and HDV among Pregnant WomenHospitalTotal number of positivesOverall seroprevalenceAntenatal clinic 1Antenatal clinic 2Antenatal clinic 3Total number tested506249250151^a^(%)Rate of biomarker (%)anti-HIV-1 antibodies11.18.43.285**8.5**HbsAg6.38.44.464**6.4**anti-HBs24.323.222.4237**23.6**HBeAg12.111.9182**8.2**anti-Hbe18.816.817.6182**18.1**anti-HBc37.028.434.8347**34.5**anti-HCV0.40.20.28**0.8**anti-HDV40**4.0**^a^Total number of women infected with HIV, HBV or HCV

Forty of the 64 HBsAg positive women were co-infected with HDV (4.0%) in Group 1. Rates of other HBV infection markers were 23.6% for anti-HBs, 8.2% for HBeAg, 18.1% for anti-HBe and 34.5% for anti-HBc (Table [4](#Tab4){ref-type="table"}).IV)**HIV Type 1 Genetic Diversity**

Analysis of 40 HIV-1 protease-reverse transcriptase sequences revealed a broad genetic diversity dominated by recombinant variants (84%), with the CRF02_AG variant most commonly detected (50%) (Fig. [1](#Fig1){ref-type="fig"}). Apart from CRFs and CRF-containing recombinants, recombinants of subtypes along the protease-reverse transcriptase region A/G (6%), D/F (2%) and K/A (4%) were also identified.V)**Frequency of HIV-1 Drug Resistance-associated Mutations**Fig. 1Distribution of HIV-1 Genetic variants. Each colour represents a HIV-1 genetic variant. The pie chart shows the proportion of each HIV-1 genetic variant identified in the study

Mutations-associated to resistance to NRTI, NNRTI and PI were detected in 9 out of 40 specimens (22.5%) (Table [5](#Tab5){ref-type="table"}).Table 5Frequency of HIV-1 Mutations associated to Resistance to different Classes of Antiretroviral (ARV) DrugsNucleo(s)tide reverse transcriptase inhibitors (NRTI)Non nucleoside reverse transcriptase inhibitors (NNRTI)Protease inhibitors (PI)Major RAMNumberFrequency (%)Major RAMNumberFrequency (%)Major RAMNumberFrequency (%)M184 V512.5K103 N512.5M46 L12.5K70R410YI8IC410L90 M12.5T215Y37.5YI88L/H/C25V75 M37.5H221Y25T215F25P225H12.5L201 W25F227 L12.5M41 L25K238 T12.5L74 V12.5K219Q/E12.5K65R12.5

Some commonly identified RAMs to NRTIs include M184 V (12.5%) and K70R (10%), and to NNRTIs were K103 N (12.5%) and Y181C (10%), and to PIs M46 L (2.5%) and L90 M (2.5%) (Table [5](#Tab5){ref-type="table"}).

Most of the women (62%) had CD4 counts \> 350 cells/ul (mean 374+/− 114 cells/mm^3^). HIV-1 plasma RNA viral load of \< 1000 copies/ml was reported for 10 participants (25%), while 6 (15%) had greater than 10,000 copies/ml. The median viral load was 4378 copies/ml (IQR: 2036--8268 copies/ml). The greatest proportion of the study subjects (68%) had viral load values between 1000 and 10,000 copies/ml.

Discussion {#Sec8}
==========

Viruses in pregnant women and their impact on the outcome of the pregnancy and infant health have not been well-studied in the era of PMTCT in Cameroon just as in several sub Saharan African countries. We found in this study that 63.8% of the HIV-infected pregnant women knew their status before pregnancy, whilst none of the HCV-infected individuals and 5.9% of the HBsAg-positive, respectively, admitted that they had known their status before pregnancy. On the other hand, we found 8.2% rate of HBeAg, a risk factor of transmission of HBV from mother-to-child \[[@CR18]\]. As declared in the Bordeaux Call of April 2018 \[[@CR19]\], WHO estimates that 0.3 and 6% of people infected with HBV and HCV, respectively, know their serologic status in Africa. The marked difference in awareness of the serologic status, between HIV-infected pregnant women and those infected with the other viruses highlights the need to promote screening of HBV, HCV and HDV in women.

We report in this study that 47.8% of the pregnant women reported sexual intercourse as a route of HBV transmission while 47.1% reported the vertical transmission route. Although 83.3% of the study population reported that vaccination against hepatitis B would reduce the risk of transmission of HBV, only 2.5% of the women reported haven been vaccinated. The seroprevalence of HIV in our study was 8.5% higher than that reported in the Demographic and Health Survey (DHS) of 7.6% in 2011 \[[@CR20]\].

Only one woman was infected with HCV in our study (0.98%), a rate which is low compared to that of HBV or HIV-1, although Ndumbe and colleagues reported a higher rate in Yaounde of 5.5, and 6.0% in a rural community in the South West Region of Cameroon \[[@CR21]\]. However, higher prevalence was found among pregnant women in bigger cities like in Benin City in Nigeria of 3.6% \[[@CR22]\]. The co-infection rate of HIV/HBV in this study was 0.5%. This was lower when compared to 9.3% reported by Kfutwah et al. among pregnant women in Yaounde with known HIV status \[[@CR23]\], and 7.4% in the general population in Cameroon \[[@CR24]\].

Antiretroviral drug resistance testing is rarely used to follow-up HIV-infected pregnant women nor infants on ART in Cameroon. A few studies have been carried out in Cameroon to determine the levels of antiretroviral drug resistance in different populations \[[@CR25]--[@CR31]\], but little has been done on HIV-1 infected women during and after pregnancy. Our study was carried out on samples from 40 HIV-infected and breastfeeding women with the goal to evaluate the pattern of ARV drug resistance in women enrolled in the PMTCT Programme and who were breastfeeding.

The prevalence of antiretroviral drug resistance in this study was 22.5% (9/40). This is higher than the findings of Boghuma and colleagues \[[@CR32]\] who evaluated ARV drug resistance in a group of Cameroonian women at 6--8 weeks after delivery and found 4 out of 31 (12.9%) with ARV drug resistant HIV-1. This indicates that ARV drug resistance in women enrolled in the PMTCT Programme in Cameroon may actually be growing following the increasing access to ART. We could however not explain this trend because the ARV drug resistance profile of these women prior to ARV exposure was not known.

Other studies have shown variable levels of drug resistance in HIV-infected women following the PMTCT Programme. The women in this study were exposed to NRTIs and NNRTIs. Of the 40 women, only 6 (15.0%) harboured HIV-1 variants with major mutations associated to NRTI resistance. Of the nine mutations, M184 V (12.5%) and K70R (10.0%) were most frequently identified. The M184 V is known to confer high levels of resistance to lamivudine (3TC) and emtricitabine (FTC), while K70R is known to confer intermediate levels of resistance to zidovudine (AZT). The high frequency of M184 V found in our study could be explained by the fact that lamivudine and zidovudine are part of PMTCT regimens in Cameroon. Meanwhile, 5 women out of 40, harboured mutations that confer resistance to NNRTIs of which K103 N (12.5%) and Y181C (10.0%) were the most frequent. Of the 9 RAMs identified, K103 N was identified in 5 women, which predicts resistance to nevirapine. Y181C as well as K103 N confer intermediate to high level resistance to nevirapine and efavirenz, two NNRTIs commonly used in Cameroon.

On the other hand, two women were found with RAMs to protease inhibitors which were M46 L (2.5%) and L90 M (2.5%). The frequency of PI mutations unlike that of NRTI and NNRTI was low in our study. This could be explained by the fact that PIs are rarely used in Cameroon, and are reserved for patients failing first line regimens which contain two NRTIs and one NNRTI. None of the participants in our study had been exposed to PI, therefore, this could have been a case of transmitted PI resistance. We report a broad genetic diversity in our study dominated by recombinant variants (84%). The most represented HIV-1 subtype in our study population was CRF02_AG (50%), similar to the findings reported from other studies \[[@CR14], [@CR28], [@CR31]\]. However, we could not determine the HBV, HCV and HDV genetic variants as well as the antiviral drug resistance pattern due to limited resources. Furthermore, we could not follow-up the infants born to virus-positive mothers to determine the rates of vertical transmission.

Conclusions {#Sec9}
===========

The rates of HBV and HIV-1 infection among pregnant women indicate that if effective prevention interventions are not offered, and sensitization of pregnant women on vertically transmissible viruses is not promoted, then we cannot fully protect the next generation of children from these infections. The frequency of HIV-1 drug resistance is high among breastfeeding women after 6 weeks postpartum. Therefore, drug resistance testing should be used to guide the choice of ART for infants who become infected by their mothers enrolled in the PMTCT Programme. The missing link therefore is the policy of screening pregnant women for other communicable diseases that can be transmitted from mother-to-child, and expand the PMTCT Programme in Cameroon. Bridging this gap is a priority and contribution to the WHO Hepatitis Elimination Initiative in a LMIC.
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3TC

:   Lamivudine
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:   Antiretroviral treatment
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:   Zidovudine

CD4

:   Cluster of Differentiation

CRF

:   Circulating Recombinant Form

DHS

:   Demographic and Health Survey

DNA

:   Deoxyribonucleic acid

EID

:   Early Infant Diagnosis

ELISA

:   Enzyme linked Immunosorbent Assay

FTC

:   Emtricitabine

HBeAg

:   Hepatitis B envelope antigen

HBsAg

:   Hepatitis B surface Antigen

HBV

:   Hepatitis B Virus

HCV

:   Hepatitis C Virus

HDV

:   Hepatitis D Virus

HIV

:   Human Immunodeficiency Virus

IRB

:   Institutional Review Board

LMIC

:   Low- and Middle- Income Countries

NACP

:   National AIDS Control Programme

NNRTI

:   Non nucleoside reverse transcriptase inhibitors

NRTI

:   Nucleoside or nucleotide reverse transcriptase inhibitors

NVP

:   Nevirapine

PI

:   Protease Inhibitors

PMTC

:   Prevention of Mother to Child Transmission

RNA

:   Ribonucleic acid

STD

:   Sexually transmitted diseases
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